Is nicotinamide adenine dinucleotide the Achilles’ heel of chronic interleukin-6 signaling in cholangiocarcinoma?

References

[1] Gehl V,O'Rourke CJ,Cornillet M.et al. Molecular and cellular consequences of tumour-autonomous IL-6 signalling in intrahepatic cholangiocarcinoma Gut 2026 Epub ahead of print

[2] Banales JM,Rodrigues PM,Affò S.et al. ; International CCA Consensus Consortium. Cholangiocarcinoma 2026: status quo, unmet needs and priorities Nat Rev Gastroenterol Hepatol 2026 23 65 96

[3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma J Hepatol 2025 83 211 38

[4] Høgdall D,O’Rourke CJ,Dehlendorff C.et al. Serum IL6 as a prognostic biomarker and IL6R as a therapeutic target in biliary tract cancers Clin Cancer Res 2020 26 5655 67 PMC8998158

[5] Zhang M,Yang H,Wan L.et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma J Hepatol 2020 73 1118 30

[6] Garten A,Schuster S,Penke M,Gorski T,de Giorgis T,Kiess W. Physiological and pathophysiological roles of NAMPT and NAD metabolism Nat Rev Endocrinol 2015 11 535 46

[7] Wei Y,Xiang H,Zhang W. Review of various NAMPT inhibitors for the treatment of cancer Front Pharmacol 2022 13 970553 PMC9490061

[8] Ramsey KM,Yoshino J,Brace CS.et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis Science 2009 324 651 4 PMC2738420

[9] Nakahata Y,Sahar S,Astarita G,Kaluzova M,Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1 Science 2009 324 654 7 PMC6501775

[10] Dang CV. A time for MYC: metabolism and therapy Cold Spring Harb Symp Quant Biol 2016 81 79 83

[11] Steffeck AWT,Cordova AA,Abdulkadir SA. MAX in cancer: dynamic role of MYC's partner-in-crime Trends Cancer 2026 12 217 20 PMC12994428